Delving into the Latest Updates on CVX-51401 with Synapse

PurposeCaveolin (Cav) regulates various aspect of endothelial cell signaling and cell-permeable peptides (CPPs) fused to domains of Cav can reduce retinal damage and inflammation in vivo. Thus, the goal of the present study was to identify a novel CPP that improves delivery of a truncated Cav modulator in vitro and in vivo.MethodsPhage display technology was used to identify a small peptide (RRPPR) that was internalized into endothelial cells. Fusions of Cav with the peptide were compared to existing molecules in three distinct assays, vascular endothelial growth factor-A (VEGF) induced nitric oxide (NO) release, VEGF induced vascular leakage, and in a model of immune mediated uveitis.ResultsRRPPR was internalized efficiently and was potent in blocking NO release. Fusing RRPPR with a minimal Cav inhibitory domain (CVX51401) dose-dependently blocked NO release, VEGF induced permeability, and retinal damage in a model of uveitis.ConclusionsCVX51401 is a novel Cav modulator that reduces VEGF and immune mediated inflammation.Translational RelevanceCVX51401 is an optimized Cav modulator that reduces vascular permeability and ocular inflammation that is poised for clinical development.

100 Deals associated with CVX-51401

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Wet age-related macular degeneration	Phase 1	US	Cavtherx, Inc.	28 Dec 2021
Dystrophy, Macular	Preclinical	US	Yale School of Medicine	14 May 2021
Dystrophy, Macular	Preclinical	US	Trefoil Therapeutics, Inc.Startup	14 May 2021
Uveitis	Preclinical	US	Trefoil Therapeutics, Inc.Startup	14 May 2021
Uveitis	Preclinical	US	Yale School of Medicine	14 May 2021
Uveitis	Preclinical	US	Cavtherx, Inc.	14 May 2021